TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04694885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Hypnotherapy
Description: The Intervention includes 10 structured hypnotherapy sessions lasting 45 to 60 minutes. During hypnosis, patients reach a trance-like state comparable to a deep relaxation. The therapist guides the patient verbally and also communicates with the patient.~Patients will be supported to use their own imagination without suggesting any imagery. By repeatedly asking what the patient is perceiving, and by verbally repeating what the patient is saying, the therapist can help the patient to go deeper into trance. In these trance states the patient learns to reduce negative side effects of the chemotherapy and increase the quality of life by activating both physical and mental resources using imagination and focusing on positive memories and feelings.
Study: NCT05142202

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Breast Irradiation after Breast-Conserving Surgery
Description: All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.
Study: NCT06062303

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (UC)
Description: - Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, heart rate (HR) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
Study: NCT05790473

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial Intelligence
Description: Development of AI algorithm for early detection of fetal brain anomalies in the first trimester of pregnancy

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial Intelligence
Description: Development of AI algorithm for early detection of fetal brain anomalies in the first trimester of pregnancy
Study: NCT06027138

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: slow motion strength training
Description: We will use slow motion strength training method. Each exercise is performed by lifting weights for approximately 10 seconds, lowering the weight for another 10 seconds, and not resting between repetitions.before receiving treatment sample muscle size and explosive strength was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press (pre test).secondly treat the arm and thigh muscles to to slow motion weight training.weight training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles. (Post test).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: slow motion strength training
Description: We will use slow motion strength training method. Each exercise is performed by lifting weights for approximately 10 seconds, lowering the weight for another 10 seconds, and not resting between repetitions.before receiving treatment sample muscle size and explosive strength was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press (pre test).secondly treat the arm and thigh muscles to to slow motion weight training.weight training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles. (Post test).
Study: NCT05582252

Intervention type: OTHER
Intervention: Non-Invasive saliva sampling
Description: There are two types of intervention in this ambidirectional study.~1. Non-Invasive Saliva Sampling will be done for DNA extraction for the purpose of genetic analysis. This would be the prospective sampling and it's not part of the related medical centre's clinical routine.~2. ICD that is already implanted in the patients and had been indicated by related medical centre's clinical routine approach. This is not a prospective approach to this study since the study would be retrospectively gathered phenotypic parameters from the hospital data records.

Intervention type: OTHER
Intervention: Non-Invasive saliva sampling
Description: There are two types of intervention in this ambidirectional study.~1. Non-Invasive Saliva Sampling will be done for DNA extraction for the purpose of genetic analysis. This would be the prospective sampling and it's not part of the related medical centre's clinical routine.~2. ICD that is already implanted in the patients and had been indicated by related medical centre's clinical routine approach. This is not a prospective approach to this study since the study would be retrospectively gathered phenotypic parameters from the hospital data records.

Intervention type: OTHER
Intervention: Non-Invasive saliva sampling
Description: There are two types of intervention in this ambidirectional study.~1. Non-Invasive Saliva Sampling will be done for DNA extraction for the purpose of genetic analysis. This would be the prospective sampling and it's not part of the related medical centre's clinical routine.~2. ICD that is already implanted in the patients and had been indicated by related medical centre's clinical routine approach. This is not a prospective approach to this study since the study would be retrospectively gathered phenotypic parameters from the hospital data records.
Study: NCT06493903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Minds, Strong Joints
Description: In this10-week physical and mental health intervention, participants will receive recommended exercise intervention and evidence-based mental health intervention for pain, depression and anxiety.
Study: NCT05472441

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mid-Ohio Food Farmacy
Description: The Food Farmacy arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mid-Ohio Food Farmacy + Cooking for Diabetes
Description: The Food Farmacy + Cooking for Diabetes Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub
Description: The Food Farmacy + Health Impact Ohio Pathways Hub Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and has social needs address through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub
Description: The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
Study: NCT06103630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oropharyngeal Exercises
Description: Oropharyngeal Exercises
Study: NCT05749679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training and audit
Description: An evaluation of the practices with clinical audit before and after the management will be carried out.Every 3 months for 2 years, the investigating physicians of the intervention group will report for these patients the modifications or cessation of treatment, modification or implementation of interventions such as physical activity or implementation of nutritional modifications. Physician investigators will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers.10 possible actions to be deployed :~1. Hygienic and dietary measures~2. Physical activity~3. Smoking cessation~4. Avoidance of nephrotoxic substances~5. Treatment of hypertension~6. Proteinuria reduction~7. Oral antidiabetics; choice~8. Optimal HBA1c~9. Statin~10. Compliance

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Routine care
Description: Physicians in the control group will receive training on the study procedures. An evaluation of practices with a clinical audit before and after the treatments will be carried out. Every 3 months for 2 years, the investigating physicians in the control group will report for these patients the modifications or cessation of treatment, the modification or implementation of interventions such as physical activity or the implementation of modifications in terms of nutrition. The investigating physicians will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers. Physician investigators in the control group will continue their care as usual.
Study: NCT06188130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active rTMS
Description: Participants recevied 20 Hz high frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed dominant side abductor pollicis brevis (APB).The patient received robotic therapy for lower extremity just after each active TMS sessions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for lower extremity just after each sham TMS sessions.
Study: NCT06103630

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mandibular advancement device
Description: Mandibular advancement device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device
Description: Mandibular advancement device
Study: NCT06188130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the Cz central (International 10/20 Electroencephalogram System) area, corresponding to the location of the dominant hemisphere lower extremity motor cortex and cathodal to the contralateral supraorbital region. The patient received robotic therapy for lower extremity just after each active tDCS sessions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for lower extremity just after each sham tDCS sessions
Study: NCT04624984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: PD-1 Inhibitor, intravenous drip, d1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
Description: PD-1 Inhibitor, intravenous drip, d1; Gemcitabine, 1000mg/m2, intravenous drip, d1,d8; Vinorelbine, 50mg/m2, PO, d1,d8; Doxorubicin Liposome, 30mg/m2, intravenous drip, d1;
Study: NCT06230809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based self-help
Description: Web-based self-help with 5 modules, lasting 5 weeks.
Study: NCT06382051

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PEST Screening group
Description: PEST Screening group
Study: NCT05820503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lower abdominis rectus sheath block
Description: Under ultrasound guidance, the probe was transversely placed at the lateral level of the umbilicus . Using the in-plane technique, the needle was advanced until the posterior aspect of the rectus muscle was penetrated. No blood and no gas were drawn back; furthermore, a small volume of saline was initially injected to ensure that the needle tip was correctly positioned. When the needle was located between the posterior rectus muscle and posterior sheath, 5ml of 0.25% ropivacaine was injected bilaterally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia infiltration
Description: Local anesthesia drugs were injected into the peri-umbilicus cord
Study: NCT05259267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Group Therapy for PTG
Description: Online Group Therapy for PTG consists of eight sessions. Each sessions have specific themes. First session: psychoeducation, normalization of the experiences and emotions. Second session: emotion regulation skills. Third session: awareness of the negative thoughts that make patients worried, anxious, feared. Forth session: restructuring of the thoughts and practicing mindfulness technics. 5. session: practicing of self-disclosure skills 6. session: creating a breast cancer story with balancing losses and gains. 7. session: sharing of the effects of breast cancer on life and developing new life priorities 8. session: making life meaning and developing new life goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Support Group
Description: Online support groups also consist of eight sessions. 1. session: introducing the program and learning the expectancies 2. session: sharing what is known about breast cancer 3. session: risk and protective factors for breast cancer 4. session: sharing side effects of surgical operation and treatments 5. session: sharing the reactions of family, close friends 6. session: patient-doctor relationship and also sharing the challenges and facilitators of healthcare system 7. session: sharing the current position in the treatment and of what has been done for improvement 8. session: sharing the reliable information sources for breast cancer and close
Study: NCT06240650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified Health- Dx™ (mHDx) study capsule
Description: The Study mHDx capsule has a mechanism that allows the mHDx to remain resident in the stomach for no more than six (6) hours. After this residency period, the Study mHDx will disassemble and pass safely through the subject's gastrointestinal system.

Intervention type: DEVICE
Group type: OTHER
Intervention: modified Health- Dx™ (mHDx) control capsule
Description: The Control mHDX capsule does not have a functional residency mechanism so it will disassemble once safely through the esophagus (within 10 minutes) and will then pass safely through the subject's gastrointestinal system.
Study: NCT05638074

Intervention type: PROCEDURE
Intervention: Interlaminar Epidural Steroid Injection
Description: The patient will be placed in the prone position and cutaneous anesthesia is performed with 3 mL of 2% prilocaine using the sterile technique. After imaging the C7-T1 space with fluoroscopy, it will be entered from the right/left paramedian part of the C7-T1 space with an 18G Touhy needle, and the C-arm will be set in the contralateral oblique position for depth determination.~Under intermittent fluoroscopic imaging, the needle will be advanced, and access to the epidural space wiil be confirmed by the loss of resistance technique. Afterwards, the epidural spread will be controlled with a contrast agent, and a mixture of 10 mg dexamethasone, 1 mL 2% lidocaine hydrochloride, and 1 mL 0.9% saline will be applied to the epidural space. The patient will be discharged with recommendations after being kept under observation for 2 hours post-procedure. All injections will be performed by the same pain medicine specialist who has at least 5 years of experience.

Intervention type: PROCEDURE
Intervention: Interlaminar Epidural Steroid Injection
Description: The patient will be placed in the prone position and cutaneous anesthesia is performed with 3 mL of 2% prilocaine using the sterile technique. After imaging the C7-T1 space with fluoroscopy, it will be entered from the right/left paramedian part of the C7-T1 space with an 18G Touhy needle, and the C-arm will be set in the contralateral oblique position for depth determination.~Under intermittent fluoroscopic imaging, the needle will be advanced, and access to the epidural space wiil be confirmed by the loss of resistance technique. Afterwards, the epidural spread will be controlled with a contrast agent, and a mixture of 10 mg dexamethasone, 1 mL 2% lidocaine hydrochloride, and 1 mL 0.9% saline will be applied to the epidural space. The patient will be discharged with recommendations after being kept under observation for 2 hours post-procedure. All injections will be performed by the same pain medicine specialist who has at least 5 years of experience.
Study: NCT04722666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821 Intravenous Injection
Description: MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29
Study: NCT05689125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Railroaded bougie
Description: Residents expose the glottis by a video laryngoscope and place the tip of bougie through the vocal cords. Then, an assistant loads an endotracheal tube on the free end of the bougie. Residents advance the endotracheal tube over the bougie and withdraw the bougie.

Intervention type: DEVICE
Group type: OTHER
Intervention: Preloaded bougie
Description: Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation using a bougie with a preloaded endotracheal tube while an assistant secures the free end of the bougie. Residents withdraw the bougie when the endotracheal tube reaches an appropriate depth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stylet
Description: Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation with the assistance of a stylet. An assistant withdraws the stylet when the tip of the endotracheal tube passes through the vocal cords. Then residents place the endotracheal tube to an appropriate depth.
Study: NCT04722666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821 Intravenous Injection
Description: MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821 Intravenous Injection
Description: MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821 Intravenous Injection
Description: MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821 Intravenous Injection
Description: MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821 Intravenous Injection
Description: MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Intravenous Injection
Description: 40 minutes IV infusion of 0.9% sodium chloride solution on Day1, Day 15 and Day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Intravenous Injection
Description: 40 minutes IV infusion of 0.9% sodium chloride solution on Day1, Day 15 and Day 29

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intravenous Injection
Description: 40 minutes IV infusion of 0.9% sodium chloride solution on Day1, Day 15 and Day 29
Study: NCT05732064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 0.2 mg/kg (25 mg/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline of same volume is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
Study: NCT06378957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Limonene
Description: Oral Limonene administered via capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Limonene
Description: Oral Limonene administered via capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Limonene
Description: Oral Limonene administered via capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Limonene
Description: Oral Limonene administered via capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: Oral delta-9-THC in ethanol vehicle administered via capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: Oral delta-9-THC in ethanol vehicle administered via capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: Oral delta-9-THC in ethanol vehicle administered via capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: Oral delta-9-THC in ethanol vehicle administered via capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: Oral delta-9-THC in ethanol vehicle administered via capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (cellulose) administered via capsule
Study: NCT04618471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific WaveWriter SCS System
Description: WaveWriter SCS Programming